Literature DB >> 26651356

Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells.

April C L Bostian1, Leena Maddukuri1, Megan R Reed1, Tatsiana Savenka1, Jessica H Hartman1, Lauren Davis1, Dakota L Pouncey1, Grover P Miller1, Robert L Eoff1.   

Abstract

Overexpression of the translesion synthesis polymerase hpol κ in glioblastomas has been linked to poor patient prognosis; however, the mechanism promoting higher expression in these tumors remains unknown. We determined that activation of the aryl hydrocarbon receptor (AhR) pathway in glioblastoma cells leads to increased hpol κ mRNA and protein levels. We blocked nuclear translocation and DNA binding by AhR in glioblastoma cells using a small-molecule and observed decreased hpol κ expression. Pharmacological inhibition of tryptophan-2,3-dioxygenase (TDO), the enzyme largely responsible for activating AhR in glioblastoma, led to a decrease in the endogenous AhR agonist kynurenine and a corresponding decrease in hpol κ protein levels. Importantly, we discovered that inhibiting TDO activity, AhR signaling, or suppressing hpol κ expression with RNA interference led to decreased chromosomal damage in glioblastoma cells. Epistasis assays further supported the idea that TDO activity, activation of AhR signaling, and the resulting overexpression of hpol κ function primarily in the same pathway to increase endogenous DNA damage. These findings indicate that upregulation of hpol κ through glioblastoma-specific TDO activity and activation of AhR signaling likely contributes to the high levels of replication stress and genomic instability observed in these tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26651356      PMCID: PMC4718841          DOI: 10.1021/acs.chemrestox.5b00452

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  41 in total

1.  DNA polymerase kappa is specifically required for recovery from the benzo[a]pyrene-dihydrodiol epoxide (BPDE)-induced S-phase checkpoint.

Authors:  Xiaohui Bi; Damien M Slater; Haruo Ohmori; Cyrus Vaziri
Journal:  J Biol Chem       Date:  2005-04-06       Impact factor: 5.157

2.  Regulation of translesion synthesis DNA polymerase eta by monoubiquitination.

Authors:  Marzena Bienko; Catherine M Green; Simone Sabbioneda; Nicola Crosetto; Ivan Matic; Richard G Hibbert; Tihana Begovic; Atsuko Niimi; Matthias Mann; Alan R Lehmann; Ivan Dikic
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

3.  The effect of aryl hydrocarbon receptor ligands on the expression of polymerase (DNA directed) kappa (Polκ), polymerase RNA II (DNA directed) polypeptide A (PolR2a), CYP1B1 and CYP1A1 genes in rat liver.

Authors:  Damian Brauze; Agnieszka Anna Rawłuszko
Journal:  Environ Toxicol Pharmacol       Date:  2012-09-16       Impact factor: 4.860

4.  Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Authors:  Jennifer A Quinn; James Pluda; M Eileen Dolan; Shannon Delaney; Richard Kaplan; Jeremy N Rich; Allan H Friedman; David A Reardon; John H Sampson; O Michael Colvin; Michael M Haglund; Anthony E Pegg; Robert C Moschel; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

5.  Polkappa protects mammalian cells against the lethal and mutagenic effects of benzo[a]pyrene.

Authors:  Tomoo Ogi; Yoichi Shinkai; Kiyoji Tanaka; Haruo Ohmori
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

6.  Unconventional ubiquitin recognition by the ubiquitin-binding motif within the Y family DNA polymerases iota and Rev1.

Authors:  Martha G Bomar; Sanjay D'Souza; Marzena Bienko; Ivan Dikic; Graham C Walker; Pei Zhou
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

7.  Pol kappa partially rescues MMR-dependent cytotoxicity of O6-methylguanine.

Authors:  Eliana Lupari; Ilenia Ventura; Francesca Marcon; Gabriele Aquilina; Eugenia Dogliotti; Paola Fortini
Journal:  DNA Repair (Amst)       Date:  2012-04-07

8.  SHPRH and HLTF act in a damage-specific manner to coordinate different forms of postreplication repair and prevent mutagenesis.

Authors:  Jia-Ren Lin; Michelle K Zeman; Jia-Yun Chen; Muh-Ching Yee; Karlene A Cimprich
Journal:  Mol Cell       Date:  2011-03-10       Impact factor: 17.970

9.  Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Amy Walker; Henry S Friedman
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

Review 10.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

View more
  13 in total

1.  Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas.

Authors:  April C L Bostian; Robert L Eoff
Journal:  Chem Res Toxicol       Date:  2016-08-15       Impact factor: 3.739

Review 2.  Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities.

Authors:  Maroof K Zafar; Robert L Eoff
Journal:  Chem Res Toxicol       Date:  2017-09-28       Impact factor: 3.739

Review 3.  Targeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability.

Authors:  Sumeet Nayak; Jennifer A Calvo; Sharon B Cantor
Journal:  Expert Opin Ther Targets       Date:  2021-01-08       Impact factor: 6.902

Review 4.  DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.

Authors:  Mathew Lozinski; Nikola A Bowden; Moira C Graves; Michael Fay; Paul A Tooney
Journal:  Cell Oncol (Dordr)       Date:  2021-05-31       Impact factor: 6.730

5.  Overexpression of IGFBP2 mRNA predicts poor survival in patients with glioblastoma.

Authors:  Qing Yuan; Hong-Qing Cai; Yi Zhong; Min-Jie Zhang; Zhi-Jian Cheng; Jia-Jie Hao; Ming-Rong Wang; Jing-Hai Wan
Journal:  Biosci Rep       Date:  2019-06-14       Impact factor: 3.840

6.  Inhibition of tryptophan 2,3-dioxygenase impairs DNA damage tolerance and repair in glioma cells.

Authors:  Megan R Reed; Leena Maddukuri; Amit Ketkar; Stephanie D Byrum; Maroof K Zafar; April C L Bostian; Alan J Tackett; Robert L Eoff
Journal:  NAR Cancer       Date:  2021-04-09

Review 7.  Cell-based immunotherapy of glioblastoma multiforme.

Authors:  Igor Bryukhovetskiy
Journal:  Oncol Lett       Date:  2022-02-23       Impact factor: 2.967

8.  A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.

Authors:  Zhuomao Mo; Pan Li; Zhirui Cao; Shijun Zhang
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

Review 9.  The Aryl Hydrocarbon Receptor and Tumor Immunity.

Authors:  Ping Xue; Jinrong Fu; Yufeng Zhou
Journal:  Front Immunol       Date:  2018-02-13       Impact factor: 7.561

Review 10.  Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.

Authors:  Lijie Zhai; April Bell; Erik Ladomersky; Kristen L Lauing; Lakshmi Bollu; Jeffrey A Sosman; Bin Zhang; Jennifer D Wu; Stephen D Miller; Joshua J Meeks; Rimas V Lukas; Eugene Wyatt; Lynn Doglio; Gary E Schiltz; Robert H McCusker; Derek A Wainwright
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.